Maxilin

Clarithromycin, the active ingredient in Maxilin, is a macrolide antibiotic presented as an intravenous formulation for intravenous use. It treats a range of bacterial infections in both adult and pediatric patients as prescribed by a healthcare professional.

GNH USA supplies Maxilin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Clarithromycin is a macrolide antibiotic used to treat infections caused by susceptible bacteria across several organ systems.

- Community‑acquired pneumonia: effective against typical and atypical pathogens, helping resolve lung infection. - Skin and soft‑tissue infections: reduces bacterial load in cellulitis, erysipelas and wound infections. - Sinusitis and otitis media: alleviates symptoms by targeting common respiratory pathogens. - Helicobacter pylori eradication: used as part of combination therapy to eliminate the bacterium. - Atypical mycobacterial infections: assists in managing infections caused by non‑tuberculous mycobacteria.

Clarithromycin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Diarrhea: loose stools, occasionally watery. - Abdominal pain: cramping or discomfort. - Altered taste: metallic or bitter sensation. - Headache: mild to moderate intensity. - Elevated liver enzymes: mild, transient increase.

Serious or Rare Side Effects: - Severe allergic reactions: rash, angioedema, anaphylaxis. - Clostridioides difficile colitis: severe diarrhea with abdominal pain. - QT interval prolongation: risk of cardiac arrhythmias. - Hepatic failure: jaundice, elevated bilirubin. - Cardiac arrhythmias: ventricular tachycardia or fibrillation. - Stevens‑Johnson syndrome: severe skin and mucous membrane involvement.

When prescribing clarithromycin, clinicians should consider several safety measures.

- Assess renal function: adjust therapy in patients with significant impairment. - Monitor liver enzymes: watch for signs of hepatotoxicity during treatment. - Check cardiac status: avoid in patients with known QT prolongation or arrhythmias. - Avoid use in patients with macrolide hypersensitivity: risk of severe hypersensitivity reactions. - Use caution in pregnancy: limited data, prescribe only if benefits outweigh potential risks. - Store at ambient temperature: keep in original container, protect from moisture and light.

Clarithromycin interacts with several medicines; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - Erythromycin: additive QT‑prolongation risk. - Cisapride: may cause serious cardiac events. - Theophylline: increased plasma concentrations leading to toxicity. - Warfarin: enhanced anticoagulant effect, risk of bleeding. - Statins (lovastatin, simvastatin): heightened risk of myopathy.

Moderate Interactions (Monitor Closely): - Carbamazepine: reduces clarithromycin levels, may diminish efficacy. - Rifampin: induces metabolism, decreasing clarithromycin exposure. - Oral contraceptives: may lower hormonal effectiveness, advise backup contraception.